Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 2/20 | 0.58 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.57 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.57 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.57 |
| ▸ | KAT6A | Q92794 | 2/20 | 0.56 |
| ▸ | GAA | P10253 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.49 |
| ▸ | PLK1 | P53350 | 1/20 | 0.46 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.44 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.44 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | CFTR | P13569 | 1/20 | 0.43 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.42 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.42 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19541405 | 0.86 | GAA (0.53) | CTSSTAS1R3TAS1R1TAS1R2KAT6A | |
| SCHEMBL6991943 | 0.84 | GAA (0.71) | CTSSTAS1R3TAS1R1TAS1R2KAT6A | |
| SCHEMBL13407881 | 0.84 | GAA (0.46) | CTSSTAS1R3TAS1R1TAS1R2KAT6A | |
| SCHEMBL30745167 | 0.84 | GAA (0.70) | GAALMNAPLK1PDK2PTGS1 | |
| SCHEMBL1267035 | 0.84 | GAA (0.70) | GAALMNAPLK1PDK2PTGS1 | |
| SCHEMBL29262415 | 0.83 | CTSS (0.56) | CTSSTAS1R3TAS1R1TAS1R2KAT6A | |
| SCHEMBL8571125 | 0.83 | CTSS (0.58) | CTSSGAALMNAPLK1PDK2 | |
| SCHEMBL13753372 | 0.82 | CTSS (0.65) | CTSSTAS1R3TAS1R1TAS1R2KAT6A | |
| SCHEMBL13752996 | 0.82 | CTSS (0.61) | CTSSTAS1R3TAS1R1TAS1R2KAT6A | |
| SCHEMBL7984064 | 0.81 | CTSS (0.63) | CTSSGAALMNAPDK2P2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130177529-A1 | Pyrazole Compounds | VIVOQUEST, INC. | 2013-07-11 | — | — | US | disclosed |
| US-20130143858-A1 | COMPOUNDS AND THEIR USE AS IKACH BLOCKERS | ASTRAZENECA AB (SE) | 2013-06-06 | — | — | US | disclosed |
| US-8361998-B2 | Compounds and their use as IKACh blockers | ASTRAZENECA AB | 2013-01-29 | — | — | US | disclosed |
| US-8329703-B2 | Pyrazole compounds | XTL BIOPHARMACEUTICALS LTD. (IL) | 2012-12-11 | — | — | US | disclosed |
| US-8329703-B2 | Pyrazole compounds | XTL BIOPHARMACEUTICALS LTD. (IL) | 2012-12-11 | — | — | US | disclosed |
| WO-2012074469-A1 | NEW IKACH BLOCKERS | ASTRAZENECA AB (SE) | 2012-06-07 | — | — | WO | disclosed |
| US-20120142659-A1 | COMPOUNDS AND THEIR USE AS IKACH BLOCKERS | ASTRAZENECA AB (SE) | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130177529-A1 | Pyrazole Compounds | MAVS, EIF2AK2, ZC3HAV1 | CTSS 1759/4885TAS1R3 2298/4885TAS1R1 3043/4885 |
| US-20130143858-A1 | COMPOUNDS AND THEIR USE AS IKACH BLOCKERS | KCNH2, KCNJ2, KCNH3 | CTSS 4715/4885TAS1R3 3687/4885TAS1R1 3249/4885 |
| US-20120142659-A1 | COMPOUNDS AND THEIR USE AS IKACH BLOCKERS | KCNH2, KCNJ2, KCNH3 | CTSS 4715/4885TAS1R3 3687/4885TAS1R1 3249/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.